Cargando…

P952: THE ROLE OF AGE IN THE LONG-TERM TREATMENT OF MULTIPLE MYELOMA - A LONGITUDINAL ANALYSIS OF REGULAR CARE DATA

Detalles Bibliográficos
Autores principales:	Steinmetz, H. T., Heinz, M., Totzke, U.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431348/ http://dx.doi.org/10.1097/01.HS9.0000846676.08129.0a

Ejemplares similares

P952: PROGNOSTIC SIGNIFICANCE OF DYNAMIC CHANGE OF MAGE-C1/CT7 IN MULTIPLE MYELOMA: TEN YEAR EXPERIENCE FROM A SINGLE CENTER
por: Dou, Xuelin, et al.
Publicado: (2023)

P1716: REGULAR HOSPITAL VISITS IMPROVE THE PROGNOSIS OF MULTIPLE MYELOMA PATIENTS
por: Li, X., et al.
Publicado: (2022)

952. Weight-Gain in Treatment Naive Newly Diagnosed HIV-Infected Persons After Initiation on Integrase Strand Inhibitor Based Treatment Regimens
por: Szep, Zsofia, et al.
Publicado: (2020)

POS-952 COVID-19 and impact on patients and staff in Tanker Foundation
por: Kumaresan, M., et al.
Publicado: (2022)

P855: SYNERGISTIC EFFICACY OF COMBINED SUMOYLATION AND PROTEASOME INHIBITION IN MULTIPLE MYELOMA
por: Keller, U., et al.
Publicado: (2022)

P1368: OUTPATIENT AUTOTRANSPLANTS FOR PERSONS WITH MULTIPLE MYELOMA
por: Sánchez-Raga, J. M., et al.
Publicado: (2022)

P1443: AUTOLOGOUS NK CELLS AS CONSOLIDATION AFTER FRONT-LINE STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA: A LONG-TERM FOLLOW-UP
por: Lund, J., et al.
Publicado: (2022)

P15: EVOLUTION OF MULTIPLE MYELOMA TREATMENT PATTERNS FROM 2015 THROUGH 2019: REAL-WORLD EVIDENCE FROM A EUROPEAN DATABASE STUDY
por: Oriol Rocafiguera, A, et al.
Publicado: (2022)

P948: REAL-WORLD EVIDENCE OF BISPHOSPHONATES FOR MULTIPLE MYELOMA
por: Muñoz, Maria Nieves Lopez, et al.
Publicado: (2023)

P800: CHARACTERIZATION OF REGULATORY T CELLS IN PATIENTS WITH MULTIPLE MYELOMA
por: Kim, Sojeong, et al.
Publicado: (2023)

P25 EFFECT OF DARATUMUMAB ON STEM CELL YIELDS IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: REPORT FROM THE MULTIPLE MYELOMA LAZIO GROUP
por: Fazio, F., et al.
Publicado: (2023)

P971: EFFECT OF DARATUMUMAB ON STEM CELL YIELDS IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: REPORT FROM THE MULTIPLE MYELOMA LAZIO GROUP.
por: Fazio, Francesca, et al.
Publicado: (2023)

P851: TARGETING GENE DEPENDENCIES IN MYC OVEREXPRESSING MULTIPLE MYELOMA
por: Hasan Bou Issa, L., et al.
Publicado: (2022)

P977: THE VENOUS THROMBOEMBOLISM RISK ASSESMENT MODELS IN MULTIPLE MYELOMA
por: Alp Kirkizlar, Tugcan, et al.
Publicado: (2023)

P850: THE EFFECT OF UROLITHIN PRODUCTION BY GUT MICROBIOTA IN MULTIPLE MYELOMA
por: Rodríguez-García, Alba, et al.
Publicado: (2023)

Comprehensive Laboratory Data Analysis to Predict the Clinical Severity of Coronavirus Disease 2019 in 1,952 Patients in Daegu, Korea
por: Yoo, Eun-Hyung, et al.
Publicado: (2022)

P09: ATTRITION RATES IN MULTIPLE MYELOMA UNDER REAL WORLD CONDITIONS – AN ANALYSIS FROM THE AUSTRIAN MYELOMA REGISTRY
por: Benda, MA, et al.
Publicado: (2022)

P938: SURVIVAL OF PATIENTS WITH MULTIPLE MYELOMA IN THE GENERAL POPULATION BASED ON DATA FROM TWO FRENCH CANCER REGISTRIES
por: Hulin, Cyrille, et al.
Publicado: (2023)

P905: IXAZOMIB-THALIDOMIDE-DEXAMETHASONE INDUCTION FOLLOWED BY IXAZOMIB OR PLACEBO MAINTENANCE IN NON-TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS; LONG-TERM RESULTS OF HOVON-126/NMSG 21.13
por: Groen, K., et al.
Publicado: (2022)

P01.15. Multiple Myeloma, chemotherapy and curcumin
por: Panutich, E, et al.
Publicado: (2012)

P956: EMMY COHORT: MANAGEMENT OF NEWLY DIAGNOSED OR RELAPSED/ REFRACTORY MULTIPLE MYELOMA IN PATIENTS AGED OF 80 YEARS AND OVER
por: Macro, M., et al.
Publicado: (2022)

P26: EXTRAMEDULLARY MULTIPLE MYELOMA: A MONOCENTRIC RETROSPECTIVE OBSERVATIONAL STUDY
por: Brescini, M, et al.
Publicado: (2022)

P1585: THE ROLE OF INTESTINAL MICROBIOME IN SYSTEMIC INFECTIONS IN PATIENTS WITH MULTIPLE MYELOMA
por: Burylev, V., et al.
Publicado: (2022)

P912: COVID19 SEVERITY AND THERAPEUTIC OPTIONS IN PATIENTS WITH MULTIPLE MYELOMA
por: Karimova, E., et al.
Publicado: (2022)

P954: MULTIPLE MYELOMA IN LATIN AMERICA CANCER REGISTRY: THE MYLACRE STUDY
por: Hungria, Vania, et al.
Publicado: (2023)

P841: MOLECULAR MECHANISMS OF RESISTANCE TO IMMUNOMODULATORS IN MULTIPLE MYELOMA: AN IN VITRO STUDY
por: Alves, Raquel, et al.
Publicado: (2023)

P859: PROGNOSTIC IMPACT OF OPIOID USE PRIOR TO DIAGNOSIS OF MULTIPLE MYELOMA
por: Brieghel, Christian, et al.
Publicado: (2023)

P939: THE RELATIONSHIP OF BONE MARROW FIBROSIS WITH EXTRAMEDULLARY DISEASE IN MULTIPLE MYELOMA
por: Konyaoglu, Hilal, et al.
Publicado: (2023)

P848: EXPRESSION PROFILE OF BCL-2 FAMILY PROTEINS IN MULTIPLE MYELOMA.
por: Sánchez, Cristina De Ramón, et al.
Publicado: (2023)

P833: MARCH5 AS A POTENTIAL THERAPEUTIC TARGET IN MULTIPLE MYELOMA
por: Bashiri, Hamed, et al.
Publicado: (2023)

P805: EXTRAMEDULLARY MULTIPLE MYELOMA: MOLECULAR PATHOGENESIS AND NOVEL THERAPEUTIC TARGETS
por: Zihala, David, et al.
Publicado: (2023)

P879: EXENT AND FLC MASS SPECTROMETRY FOR SEROLOGICAL IDENTIFICATION AND QUANTIFICATION OF MONOCLONAL IMMUNOGLOBULINS IN MULTIPLE MYELOMA
por: Huhn, S., et al.
Publicado: (2022)

P830: IDENTIFICATION OF NOVEL TARGET GENES CORRELATED WITH 1Q21 AMPLIFICATION IN PATIENTS WITH SMOLDERING MYELOMA AND MULTIPLE MYELOMA
por: Thomas Iannozzi, Nicolas, et al.
Publicado: (2023)

Clinical Effectiveness and Long-Term Serologic Responses of COVID-19 Vaccination in Patients with Multiple Myeloma and Waldenström Macroglobulinemia
por: Branagan, Andrew R., et al.
Publicado: (2022)

Long-term survival in multiple myeloma
por: João, Cristina, et al.
Publicado: (2014)

P972: INDIRECT COMPARISON OF TECLISTIMAB IN MAJESTEC-1 VERSUS PHYSICIAN’S CHOICE OF THERAPY IN LONG-TERM FOLLOW-UP OF TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA IN DARATUMUMAB TRIALS
por: Weisel, K., et al.
Publicado: (2022)

P981: DISEASE CHARACTERISTICS AND TREATMENT OUTCOMES OF MYELOMA PATIENTS <50 YEARS OF AGE: AN ANALYSIS OF THE BALKAN MYELOMA STUDY GROUP
por: Kastritis, Efstathios, et al.
Publicado: (2023)

P874: LONG-TERM REMISSION AND SURVIVAL IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AFTER TREATMENT OF LCAR-B38M CAR-T – AT LEAST 5-YEAR FOLLOW-UP IN LEGEND-2
por: MI, Jian‑qing, et al.
Publicado: (2023)

P916: LONG-TERM OUTCOMES WITH ISATUXIMAB-CARFILZOMIB-DEXAMETHASONE (ISA-KD) IN RELAPSED MULTIPLE MYELOMA PATIENTS WITH 1Q21+ STATUS: UPDATED RESULTS FROM THE PHASE 3 IKEMA STUDY
por: Facon, Thierry, et al.
Publicado: (2023)

P02: PROGNOSTIC STRATIFICATION OF STANDARD RISK MULTIPLE MYELOMA DEFINED BY REVISED ISS
por: Barilà, G, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ashqfet926v66fj0a7h4o9aqrg